SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48